BamSEC and AlphaSense Join Forces
Learn More

Senti Biosciences Inc.

NASDAQ: SNTI    
Share price (12/23/24): $4.00    
Market cap (12/23/24): $18.4 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.4
from 8-K 8 pages Designation Agreement December 2, 2024
12/34/56
EX-10.3
from 8-K 8 pages Designation Agreement December 2, 2024
12/34/56
EX-10.2
from 8-K 20 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 53 pages Securities Purchase Agreement
12/34/56
EX-10.3
from 10-Q 5 pages Storage License Agreement
12/34/56
EX-10.2
from 10-Q 29 pages Sublease Two Corporate Drive, First Floor South San Francisco, Ca
12/34/56
EX-10.4
from 10-Q 10 pages Senti Biosciences, Inc. Consulting Agreement Effective Date: May 3, 2024
12/34/56
EX-10.3
from 10-Q 11 pages Senti Biosciences, Inc. Amended and Restated Consulting Agreement Effective Date: May 4, 2024
12/34/56
EX-10.1
from 10-Q 34 pages Sublease Agreement
12/34/56
EX-10.1
from 8-K 79 pages Amended and Restated Chef Purchase Agreement
12/34/56
EX-10.41
from 10-K 35 pages Collaboration and Option Agreement
12/34/56
EX-10.4
from 10-Q 16 pages Sublease Agreement
12/34/56
EX-10.3
from 10-Q 56 pages Development and Manufacturing Services Agreement
12/34/56
EX-10.2
from 10-Q 10 pages Seller Economic Share Agreement
12/34/56
EX-10.1
from 10-Q 65 pages Framework Agreement by and Among Senti Biosciences, Inc., Valere Bio, Inc. and Genefab, LLC Dated as of August 7, 2023
12/34/56
EX-10.8
from POS AM 11 pages August 7, 2023 Genefab, LLC 1101 Marina Village Parkway Suite 201 Alameda, Ca 94501 Re: Option to Purchase Shares of Common Stock Ladies and Gentlemen
12/34/56
EX-10.1
from 10-Q 12 pages May 10, 2022 Kanya Rajangam via Email Re: Offer of Employment 1. Commencement of Employment. Your Employment With the Company Will Commence on July 5, 2022 (The “Effective Date”)
12/34/56
EX-10.34
from 10-K 8 pages Senti Biosciences, Inc. Scientific Advisory Board Agreement
12/34/56
EX-10.33
from 10-K 3 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. February 3, 2023
12/34/56
EX-10.32
from 10-K 2 pages Amendment No. 1 to the Research Collaboration and License Agreement Between Spark Therapeutics, Inc. and Senti Biosciences, Inc
12/34/56